<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Weeks | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/slopepatio2/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/slopepatio2/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Weeks.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">0953f11d2c98775c1367e6d9134032d9</guid>
				<title>Weeks posted an update: Cold physical plasma is a partially ionized gas expelling [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42246/</link>
				<pubDate>Sun, 09 Feb 2025 08:34:10 -0800</pubDate>

									<content:encoded><![CDATA[<p>Cold physical plasma is a partially ionized gas expelling many reactive oxygen and nitrogen species (ROS/RNS). Several plasma devices have been licensed for medical use in dermatology, and recent experimental studies suggest their putative role in cancer treatment. In cancer therapies with an immunological dimension, successful antigen&hellip;<span class="activity-read-more" id="activity-read-more-42246"><a href="http://www.nationalboardinstitute.com/activity/p/42246/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">2c400c6102ad3417eb97a2a5be3dfc15</guid>
				<title>Weeks posted an update: In the same cell line, the hydroxamate 11 c and the a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36986/</link>
				<pubDate>Mon, 03 Feb 2025 08:36:19 -0800</pubDate>

									<content:encoded><![CDATA[<p>In the same cell line, the hydroxamate 11 c and the anilide 10 b induced about 30 % apoptosis, and the anilide 12 c displayed about 40 % cytodifferentiation. Finally, the most potent compounds in leukemia cells 9 b, 11 c, 10 b, 10 e, and 12 c were also tested in K562, HCT116, and A549 cancer cells, displaying antiproliferative IC50 values at sing&hellip;<span class="activity-read-more" id="activity-read-more-36986"><a href="http://www.nationalboardinstitute.com/activity/p/36986/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e4a5a4a825f2c14fe259d0f8a9351284</guid>
				<title>Weeks posted an update: Collectively, the combined design principles adopted for [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35153/</link>
				<pubDate>Sat, 01 Feb 2025 08:25:14 -0800</pubDate>

									<content:encoded><![CDATA[<p>Collectively, the combined design principles adopted for carrier-free nanodrugs construction in this study aimed at targeting different intracellular organelles for facilitating ROS production and DNA disruption can be extended to other carrier-free nanodrugs-dependent therapeutic systems.Pericytes have the potential to be developed as a cell&hellip;<span class="activity-read-more" id="activity-read-more-35153"><a href="http://www.nationalboardinstitute.com/activity/p/35153/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">20a56629f09a2c79e6e54de0232d3bba</guid>
				<title>Weeks posted an update: The emerging SARS-CoV-2 variants of concern (VoC), B.1.1.7, [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28083/</link>
				<pubDate>Tue, 28 Jan 2025 10:30:49 -0800</pubDate>

									<content:encoded><![CDATA[<p>The emerging SARS-CoV-2 variants of concern (VoC), B.1.1.7, B.1.351 and P.1, with increased transmission and/or immune evasion, emphasise the need for broad and rapid variant monitoring. Our high-volume laboratory introduced a PCR variant assay (Variant PCR) in January 2021 based on the protocol by Vogels et al. STUDY DESIGN To assess whether&hellip;<span class="activity-read-more" id="activity-read-more-28083"><a href="http://www.nationalboardinstitute.com/activity/p/28083/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">bc1e2e198a9a66f47368e3e8403b92b7</guid>
				<title>Weeks became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28015/</link>
				<pubDate>Tue, 28 Jan 2025 10:26:19 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>